C Lerman

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Health Psychol 16:87-99. 1997
  2. ncbi Tryptophan hydroxylase gene variant and smoking behavior
    C Lerman
    Psychiatry Department, University of Pennsylvania Health Sciences, Philadelphia, PA, USA
    Am J Med Genet 105:518-20. 2001
  3. ncbi What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Oncol 16:1650-4. 1998
  4. ncbi Evidence suggesting the role of specific genetic factors in cigarette smoking
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 4104, USA
    Health Psychol 18:14-20. 1999
  5. ncbi Genetic testing in families with hereditary nonpolyposis colon cancer
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 4104, USA
    JAMA 281:1618-22. 1999
  6. ncbi Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, 20007, USA
    Prev Med 31:75-80. 2000
  7. pmc Association of BDNF and COMT genotypes with cognitive processing of anti-smoking PSAs
    M Falcone
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    Genes Brain Behav 10:862-7. 2011
  8. pmc Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy
    C Lerman
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 87:553-7. 2010
  9. ncbi Parental communication of BRCA1/2 genetic test results to children
    K P Tercyak
    Lombardi Cancer Center, Georgetown University Medical Center, 2233 Wisconsin Avenue NW, Suite 317, 20007, Washington, DC 20007, USA
    Patient Educ Couns 42:213-24. 2001
  10. ncbi Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants
    K P Tercyak
    Lombardi Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
    Psychooncology 10:336-46. 2001

Collaborators

Detail Information

Publications41

  1. ncbi Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Health Psychol 16:87-99. 1997
    ..In the context of QSC, genetic feedback may heighten vulnerability and possibly promote distress, but may not immediately enhance quitting in most smokers...
  2. ncbi Tryptophan hydroxylase gene variant and smoking behavior
    C Lerman
    Psychiatry Department, University of Pennsylvania Health Sciences, Philadelphia, PA, USA
    Am J Med Genet 105:518-20. 2001
    ..Future family-based studies are needed to confirm this finding. Published 2001 Wiley-Liss, Inc...
  3. ncbi What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Oncol 16:1650-4. 1998
    ..To identify members of hereditary breast and ovarian cancer families who are at risk for adverse psychologic effects of genetic testing...
  4. ncbi Evidence suggesting the role of specific genetic factors in cigarette smoking
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 4104, USA
    Health Psychol 18:14-20. 1999
    ..This study provides preliminary evidence that the SLC6A3 gene may influence smoking initiation and nicotine dependence...
  5. ncbi Genetic testing in families with hereditary nonpolyposis colon cancer
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 4104, USA
    JAMA 281:1618-22. 1999
    ..Genetic testing for hereditary nonpolyposis colon cancer (HNPCC) is available, but the rates of acceptance of testing or barriers to participation are not known...
  6. ncbi Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing
    C Lerman
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, 20007, USA
    Prev Med 31:75-80. 2000
    ..Although genetic testing for breast cancer risk is clinically available, its impact on health-related behaviors is unknown. This study examined prophylactic surgery and surveillance behavior during the year following BRCA1/2 gene testing...
  7. pmc Association of BDNF and COMT genotypes with cognitive processing of anti-smoking PSAs
    M Falcone
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    Genes Brain Behav 10:862-7. 2011
    ..To our knowledge, this is the first study to identify genetic factors associated with cognitive processing of anti-smoking PSAs...
  8. pmc Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy
    C Lerman
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 87:553-7. 2010
    ..RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism...
  9. ncbi Parental communication of BRCA1/2 genetic test results to children
    K P Tercyak
    Lombardi Cancer Center, Georgetown University Medical Center, 2233 Wisconsin Avenue NW, Suite 317, 20007, Washington, DC 20007, USA
    Patient Educ Couns 42:213-24. 2001
    ..Research is needed to evaluate the process and content of post-test disclosure episodes and the impact on participant, child, and family functioning...
  10. ncbi Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants
    K P Tercyak
    Lombardi Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
    Psychooncology 10:336-46. 2001
    ..To the extent that learning about a parent's positive test result could exacerbate these tendencies, recommendations to promote child psychological and family communications research that monitor such responses are offered...
  11. ncbi Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women
    M D Schwartz
    Department of Oncology, Georgetown University, 2233 Wisconsin Avenue NW, Washington, DC 20007, USA
    Cancer 92:932-40. 2001
    ..The goal of the current study was to examine whether a brief educational booklet regarding BRCA1/BRCA2 testing would influence knowledge, attitudes, and interest in testing among Ashkenazi Jewish women from the general population...
  12. ncbi Spiritual faith and genetic testing decisions among high-risk breast cancer probands
    M D Schwartz
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Epidemiol Biomarkers Prev 9:381-5. 2000
    ..2; 95% CIs, 0.4 and 3.0). These results highlight the role that spirituality may play in the decision-making process about genetic testing...
  13. ncbi Association of OPRM1 A118G variant with the relative reinforcing value of nicotine
    R Ray
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, 19104, USA
    Psychopharmacology (Berl) 188:355-63. 2006
    ..We examined (1) the association of the functional OPRM1 A118G variant with the relative reinforcing value of nicotine and (2) the main and interacting effects of the mu-opioid receptor antagonist naltrexone on nicotine reinforcement...
  14. doi Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence
    R Ray
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    J Psychopharmacol 23:168-76. 2009
    ..However, atomoxetine had no effect on any of the cognitive tasks employed in the study. Thus, atomoxetine may reduce cravings to smoke among smokers who use nicotine to increase arousal...
  15. ncbi BRCA1/2 testing: complex themes in result interpretation
    B N Peshkin
    Department of Oncology Division of Cancer Control, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
    J Clin Oncol 19:2555-65. 2001
    ..A multidisciplinary approach to service delivery, which includes clinicians in genetics and oncology, can facilitate patients' decision making and provide continued access to information and support...
  16. ncbi Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk
    K P Tercyak
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 4104, USA
    Health Psychol 20:217-22. 2001
    ..After test results were disclosed, greater distress was associated with testing positive for a mutation. The implications of the findings for breast and ovarian cancer patients are discussed...
  17. ncbi Intention to be tested for prostate cancer risk among African-American men
    R E Myers
    Division of Medical Oncology and Medical Genetics, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Epidemiol Biomarkers Prev 9:1323-8. 2000
    ..Intention to be tested for prostate cancer risk was high among men in the study. Past screening, perceived susceptibility, and beliefs related to early detection might influence receptivity to genetic testing for prostate cancer risk...
  18. doi Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion
    F Patterson
    Department of Psychiatry, Transdisciplinary Tobacco Use Research Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 84:320-5. 2008
  19. ncbi Attention-Deficit Hyperactivity Disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program
    C Lerman
    University of Pennsylvania, 3535 Market St, Suite 4100, Philadelphia, PA 19104, USA
    Nicotine Tob Res 3:353-9. 2001
    ..Future studies of the role of inattention symptoms in response to smoking treatment are warranted...
  20. pmc A randomized trial of breast cancer risk counseling: the impact on self-reported mammography use
    M D Schwartz
    Georgetown University Medical Center Lombardi Cancer Center, Cancer Genetics, Washington, DC 20007, USA
    Am J Public Health 89:924-6. 1999
    ..We evaluated the impact of individualized breast cancer risk counseling on mammography use among women at risk for breast cancer...
  21. ncbi Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial
    J Audrain
    Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC 20007, USA
    Addict Behav 22:741-51. 1997
    ..Genetic susceptibility feedback has the intended effects on motivation to quit, but it may need to be delivered within a more intensive smoking-cessation treatment for the heightened motivation to translate into smoking cessation...
  22. ncbi Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations
    W F Lawrence
    Cancer Clinical and Economic Outcomes Division of Cancer Prevention and Control, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
    Cancer Epidemiol Biomarkers Prev 10:475-81. 2001
    ..The cost of detecting a mutation within a population of women is highly dependent on the prevalence of the mutation in the population...
  23. ncbi Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence
    J P Dahl
    Department of Psychiatry, Center for Neurobiology and Behavior, University of Pennsylvania, Philadelphia, PA 19104, USA
    Pharmacogenomics J 6:194-9. 2006
    ..This result suggests that the interaction between variation in the DRD2 and FREQ genes, which both encode components of the D2 dopamine receptor signal transduction pathway, impacts the efficacy of NRT...
  24. pmc Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype
    J Loughead
    Brain Behavior Laboratory, Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Psychiatry 14:820-6. 2009
    ..Exploration of the effects of COMT inhibitors as a possible smoking cessation aid in this group may be warranted...
  25. ncbi Consent to the use of stored DNA for genetics research: a survey of attitudes in the Jewish population
    M D Schwartz
    Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, 2233 Wisconsin Ave NW, Suite 317, Washington, DC 20007, USA
    Am J Med Genet 98:336-42. 2001
    ..Finally, participants were significantly less willing to participate in research that examined stereotypical or potentially stigmatizing traits as opposed to research that examined medical or mental illnesses...
  26. doi Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment
    D F Heitjan
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    Pharmacogenomics J 8:391-9. 2008
    ....
  27. pmc APOE ɛ4, an Alzheimer's disease susceptibility allele, and smoking cessation
    R L Ashare
    Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Pharmacogenomics J 13:538-43. 2013
    ..An increased understanding of the underlying pathophysiological mechanisms of this association could facilitate the development of targeted therapies for smokers with increased risk for cognitive decline. ..
  28. pmc Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence
    J R Turner
    Department of Pharmacology, Translational Research Laboratories, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Mol Psychiatry 19:801-10. 2014
    ..Although the function of the SNP in NRG3 in humans is not known, these data suggest that Nrg3/ErbB4 signaling may be an important factor in nicotine dependence. ..
  29. ncbi The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial
    C Lerman
    Department of Psychiatry, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
    Pharmacogenomics J 4:184-92. 2004
    ..Smokers who carry the OPRM1 Asp40 variant are likely to have a favorable response to TN and may benefit from extended therapy with the 21 mg dose...
  30. ncbi Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials
    S J Siegel
    Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuroscience 133:729-38. 2005
    ....
  31. ncbi Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
    I B Runnebaum
    Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany
    Pharmacogenetics 11:635-8. 2001
    ..4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth...
  32. ncbi Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group
    S A Narod
    Centre for Research on Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Lancet 356:1876-81. 2000
    ..Tamoxifen protects against contralateral breast cancer in the general population, but whether it protects against contralateral breast cancer in BRCA1 or BRCA2 mutation carriers is not known...
  33. pmc Is Swedish snus associated with smoking initiation or smoking cessation?
    H Furberg
    Department of Genetics, University of North Carolina, Chapel Hill, NC 27599 7264, USA
    Tob Control 14:422-4. 2005
    ..Evaluation of the efficacy of snus for smoking cessation should be evaluated in randomised clinical trials...
  34. ncbi Patterns of breast cancer screening among lesbians at increased risk for breast cancer
    C B Burnett
    The Lesbian Health Clinic of Whitman Walker and The Mautner Project for Lesbians with Cancer
    Women Health 29:35-55. 1999
    ....
  35. ncbi Nicotine metabolism and CYP2D6 phenotype in smokers
    N E Caporaso
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 7372, USA
    Cancer Epidemiol Biomarkers Prev 10:261-3. 2001
    ....
  36. doi Development of procedures for early screening of smoking cessation medications in humans
    K A Perkins
    Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Pharmacol Ther 84:216-21. 2008
    ..Intrinsic, but not extrinsic, quit motivation of participants may enhance the validity of brief tests of medication efficacy for smoking cessation...
  37. ncbi Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms
    J Erblich
    Derald H Ruttenberg Cancer Center, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Pharmacogenomics J 4:102-9. 2004
    ....
  38. doi Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?
    A E Shields
    Harvard MGH Center on Genomics, Vulnerable Populations, and Health Disparities, Boston, Massachusetts, USA
    Clin Pharmacol Ther 83:635-9. 2008
    ....
  39. ncbi Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers
    J Erblich
    Department of Oncological Sciences, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Mol Psychiatry 10:407-14. 2005
    ..0006), reflecting additive effects. Findings provide support for the role of dopamine in cue-induced craving in humans, and suggest a possible genetic risk factor for persistent smoking behavior in African-American smokers...
  40. ncbi Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
    V Malaiyandi
    Centre for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, ON, Canada
    Mol Psychiatry 11:400-9. 2006
    ..5+/-8.0, respectively, P<0.02). These findings indicate that CYP2A6 genotype influences smoking behaviour in a Caucasian treatment-seeking population and that CYP2A6 genotype affects plasma levels obtained from, and usage of, NRT...
  41. ncbi CREB1 haplotypes and the relative reinforcing value of nicotine
    R Ray
    Mol Psychiatry 12:615-7. 2007